Nanjing Pharmaceutical Group Company Limited (SHA:600713)
China
· Delayed Price · Currency is CNY 5.35
-0.02 (-0.37%)
At close: Mar 9, 2026
SHA:600713 Revenue
Nanjing Pharmaceutical Group Company had revenue of 13.17B CNY in the quarter ending September 30, 2025, a decrease of -3.93%. This brings the company's revenue in the last twelve months to 53.89B, down -0.16% year-over-year. In the year 2024, Nanjing Pharmaceutical Group Company had annual revenue of 53.70B with 0.20% growth.
Revenue (ttm)
53.89B
Revenue Growth
-0.16%
P/S Ratio
0.13
Revenue / Employee
11.16M
Employees
4,830
Market Cap
7.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.70B | 106.51M | 0.20% |
| Dec 31, 2023 | 53.59B | 3.37B | 6.71% |
| Dec 31, 2022 | 50.22B | 5.10B | 11.30% |
| Dec 31, 2021 | 45.12B | 5.31B | 13.33% |
| Dec 31, 2020 | 39.82B | 2.66B | 7.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai InnoStar Bio-tech | 811.33M |
| Zhejiang Int'l Group | 33.54B |
| GuangYuYuan Chinese Herbal Medicine | 1.39B |
| Hunan Jingfeng Pharmaceutical | 393.19M |
| Chongqing Lummy Pharmaceutical | 771.02M |
| Hangzhou Minsheng Healthcare | 744.06M |
| Hangzhou Bio-Sincerity Pharma-Tech | 590.33M |
| Shandong Keyuan Pharmaceutical | 435.52M |